tiprankstipranks
Advertisement
Advertisement

OMER Stock Latest News

Omeros Earnings Call: YARTEMLEA Fuels a New Phase
Company AnnouncementsOmeros Earnings Call: YARTEMLEA Fuels a New Phase
2d ago
OMER
Omeros’ $100 Million Buyback Plan Heightens Volatility and Valuation Risk for Shareholders
PremiumCompany Announcements
Omeros’ $100 Million Buyback Plan Heightens Volatility and Valuation Risk for Shareholders
7d ago
OMER
Omeros Earnings Call: YARTEMLEA Launch Drives New Phase
PremiumCompany Announcements
Omeros Earnings Call: YARTEMLEA Launch Drives New Phase
7d ago
OMER
Omeros reports Q1 adjusted EPS (24c), consensus (28c)
PremiumThe Fly
Omeros reports Q1 adjusted EPS (24c), consensus (28c)
9d ago
OMER
Omeros options imply 10.8% move in share price post-earnings
PremiumThe Fly
Omeros options imply 10.8% move in share price post-earnings
9d ago
OMER
Kyverna Therapeutics appoints Nadia Dac as chief commercial officer
PremiumThe FlyKyverna Therapeutics appoints Nadia Dac as chief commercial officer
18d ago
KYTX
OMER
Sagimet Biosciences appoints Grauer as Chief Medical Officer
Premium
The Fly
Sagimet Biosciences appoints Grauer as Chief Medical Officer
1M ago
OMER
SGMT
Omeros says CMS assigns permanent reimbursement J-code for YARTEMLEA
Premium
The Fly
Omeros says CMS assigns permanent reimbursement J-code for YARTEMLEA
1M ago
OMER
Omeros Turns Corner With Novo Deal, YARTEMLEA Launch
PremiumCompany Announcements
Omeros Turns Corner With Novo Deal, YARTEMLEA Launch
2M ago
OMER
Closing Bell Movers: Nike slides 9% after Q3 results, soft outlook
PremiumThe Fly
Closing Bell Movers: Nike slides 9% after Q3 results, soft outlook
2M ago
RH
NKE
Omeros reports Q4 EPS $1.22, consensus 36c
PremiumThe Fly
Omeros reports Q4 EPS $1.22, consensus 36c
2M ago
OMER
Omeros Corporation (OMER) Q4 Earnings Cheat Sheet
PremiumPre-Earnings
Omeros Corporation (OMER) Q4 Earnings Cheat Sheet
3M ago
OMER
Omeros: YARTEMLEA Cash Flows Funding High-Upside OncotoX-AML Pipeline, Supporting Buy Rating and $40 Target
PremiumRatingsOmeros: YARTEMLEA Cash Flows Funding High-Upside OncotoX-AML Pipeline, Supporting Buy Rating and $40 Target
3M ago
OMER
Omeros announces completion of nonhuman primates OncotoX-AML study
Premium
The Fly
Omeros announces completion of nonhuman primates OncotoX-AML study
3M ago
OMER
Omeros announces first commercial sales of Yartemlea
Premium
The Fly
Omeros announces first commercial sales of Yartemlea
4M ago
OMER
Balanced Risk/Reward and Gradual Yartemlea Ramp Justify Hold Rating on Omeros
PremiumRatings
Balanced Risk/Reward and Gradual Yartemlea Ramp Justify Hold Rating on Omeros
4M ago
OMER
Omeros price target raised to $40 from $20 at H.C. Wainwright
PremiumThe Fly
Omeros price target raised to $40 from $20 at H.C. Wainwright
4M ago
OMER
Omeros call volume above normal and directionally bullish
PremiumThe Fly
Omeros call volume above normal and directionally bullish
5M ago
OMER
Omeros call volume above normal and directionally bullish
PremiumThe Fly
Omeros call volume above normal and directionally bullish
5M ago
OMER
D. Boral Capital notes Omeros’ YARTEMLEA FDA win, maintains Buy rating
PremiumThe FlyD. Boral Capital notes Omeros’ YARTEMLEA FDA win, maintains Buy rating
5M ago
OMER
Omeros: YARTEMLEA Approval and Novo Nordisk Partnership Drive Re‑Rating Potential and Support Buy Rating
Premium
Ratings
Omeros: YARTEMLEA Approval and Novo Nordisk Partnership Drive Re‑Rating Potential and Support Buy Rating
5M ago
OMER
H.C. Wainwright says Yartemlea approval ‘significant validation’ of Omeros value
Premium
The Fly
H.C. Wainwright says Yartemlea approval ‘significant validation’ of Omeros value
5M ago
OMER

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >